Genetic instability and increased mutational load

Which diagnostic tool best direct patients with cancer to immunotherapy?

Giuseppe Palmieri, Maria Colombino, Antonio Cossu, Antonio Marchetti, Gerardo Botti, Paolo A. Ascierto

Research output: Contribution to journalComment/debate

15 Citations (Scopus)

Abstract

The occurrence of high rates of somatic mutations in cancer is believed to correspond to increased frequency of neo-epitope formation and tumor immunogenicity. Thus, classification of patients with cancer according to degree a somatic hyper-mutational status could be proposed as a predictive biomarker of responsiveness to immunotherapy with immune checkpoint inhibitors. Here, we discuss the suitable and reliable tests easily adoptable in clinical practice to assess somatic mutational status in patients with advanced cancer.

Original languageEnglish
Article number17
JournalJournal of Translational Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 21 2017

Fingerprint

Biomarkers
Immunotherapy
Tumors
Epitopes
Neoplasms
Mutation Rate

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Genetic instability and increased mutational load : Which diagnostic tool best direct patients with cancer to immunotherapy? / Palmieri, Giuseppe; Colombino, Maria; Cossu, Antonio; Marchetti, Antonio; Botti, Gerardo; Ascierto, Paolo A.

In: Journal of Translational Medicine, Vol. 15, No. 1, 17, 21.01.2017.

Research output: Contribution to journalComment/debate

@article{34a28d6dfc9b4f32a1ac335c7ddc09b0,
title = "Genetic instability and increased mutational load: Which diagnostic tool best direct patients with cancer to immunotherapy?",
abstract = "The occurrence of high rates of somatic mutations in cancer is believed to correspond to increased frequency of neo-epitope formation and tumor immunogenicity. Thus, classification of patients with cancer according to degree a somatic hyper-mutational status could be proposed as a predictive biomarker of responsiveness to immunotherapy with immune checkpoint inhibitors. Here, we discuss the suitable and reliable tests easily adoptable in clinical practice to assess somatic mutational status in patients with advanced cancer.",
author = "Giuseppe Palmieri and Maria Colombino and Antonio Cossu and Antonio Marchetti and Gerardo Botti and Ascierto, {Paolo A.}",
year = "2017",
month = "1",
day = "21",
doi = "10.1186/s12967-017-1119-6",
language = "English",
volume = "15",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Genetic instability and increased mutational load

T2 - Which diagnostic tool best direct patients with cancer to immunotherapy?

AU - Palmieri, Giuseppe

AU - Colombino, Maria

AU - Cossu, Antonio

AU - Marchetti, Antonio

AU - Botti, Gerardo

AU - Ascierto, Paolo A.

PY - 2017/1/21

Y1 - 2017/1/21

N2 - The occurrence of high rates of somatic mutations in cancer is believed to correspond to increased frequency of neo-epitope formation and tumor immunogenicity. Thus, classification of patients with cancer according to degree a somatic hyper-mutational status could be proposed as a predictive biomarker of responsiveness to immunotherapy with immune checkpoint inhibitors. Here, we discuss the suitable and reliable tests easily adoptable in clinical practice to assess somatic mutational status in patients with advanced cancer.

AB - The occurrence of high rates of somatic mutations in cancer is believed to correspond to increased frequency of neo-epitope formation and tumor immunogenicity. Thus, classification of patients with cancer according to degree a somatic hyper-mutational status could be proposed as a predictive biomarker of responsiveness to immunotherapy with immune checkpoint inhibitors. Here, we discuss the suitable and reliable tests easily adoptable in clinical practice to assess somatic mutational status in patients with advanced cancer.

UR - http://www.scopus.com/inward/record.url?scp=85009999839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009999839&partnerID=8YFLogxK

U2 - 10.1186/s12967-017-1119-6

DO - 10.1186/s12967-017-1119-6

M3 - Comment/debate

VL - 15

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 17

ER -